Abstract
In the last 15 years, the evolution of therapies proposed for the management of Parkinson’s disease has represented a real challenge for clinicians to select the best methodology for their evaluation. Since the spectacular introduction of levodopa, accurate and reliable assessment techniques have been extensively developed for testing drug efficacy in parkinsonism. A large and growing body of literature on Parkinson’s disease has been published since 1973, especially on the use of new drugs and their efficacy, with more agents than ever being evaluated in the last decade. However, less than 10% of the publications on the use of antiparkinsonian drugs in clinical trials included any form of control group (figure 11.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Calne, D. B., Leigh, P. N., Bamji, A. N., Teychenne, P. F. and Greenacre, J. K. (1974). Treatment of Parkinson on bromocriptine. Lancet, 2, 1355–6.
Calne, D. B., Stern, G. M. and Laurence, D. R. (1979). L-Dopa in post-encephalitic parkinsonism. Lancet, 1, 744–6.
Cotzias, G. C., Van Woert, M. H. and Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. New Engl. J. Med., 276, 374–9.
Eisler, T., Teravainen, H., Nelson, R., Krebs, H., Weis, V., Lake, C. R., Ebert, M. H., Whetzel, N., Murphy, D. L., Kopin, I. J. and Calne, D. B. (1981). Deprenyl in Parkinson’s disease. Neurology, 31, 19–23.
Fahn, S. (1982). Fluctuations of disability in Parkinson’s disease: pathological aspects. In Marsden, C. D. and Fahn, S. (eds), Movement Disorders. Butterworth Scientific, London, pp. 96–122.
Fahn, S. and Bressman, S. B. (1984). Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can. J. Neurol. Sci., 11 (1), 200–5.
Gopinathan, G., Teravainen, H., Dambrosia, J. M., Ward, C. D., Sanes, J. N., Stuart, W. K., Evarts, E. V. and Calne, D. B. (1981). Lisuride in parkinsonism. Neurology, 31, 371–6.
Grimes, J. D. (1984). Bromocriptine in Parkinson’s disease: results obtained with high and low dose therapy. Can. J. Neurol. Sci., 11 (1), 225–8.
Ilson, J., Fahn, S., Mayeux, R., Cote, L. J. and Snider, S. R. (1983). Pergolide treatment in parkinsonism. In Fahn, S., Calne, D. B. and Shoulson, I. (eds), Advances in Neurology, vol. 37: Experimental Therapeutics of Movement Disorders. Raven Press, New York, pp. 85–94.
Jankovic, J. (1983). Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy. Neurology, 33, 505–7.
Klawans, H. L., Tanner, C. M., Glatt, S. and Goetz, C. G. (1983). A 6-month trial period of pergolide mesylate in the treatment of idiopathic Parkinson’s disease. In Fahn, S., Calne, D. B. and Shoulson, I. (eds), Advances in Neurology, vol. 37: Experimental Therapeutics of Movement Disorders. Raven Press, New York, pp. 75–83.
Lees, A. J. and Stern, G. M. (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. Res. Clin. Forums, 3 (2) 29–35.
Le Witt, P. A., Gopinathan, G., Ward, C. D., Sanes, J. N., Dambriosia, J. M., Durso, R. and Calne, D. B. (1982). Lisuride versus bromocriptine treatment in Parkinson’s disease: a double-blind study. Neurology, 32, 69–72.
Le Witt, P. A., Burns, R. S. and Calne, D. B. (1983). Lisuride treatment in Parkinson’s disease: clinical and pharmacokinetic studies. In Fahn, S., Calne, D. B. and Shoulson, I. (eds), Advances in Neurology, vol. 37: Experimental Therapeutics of Movement Disorders. Raven Press, New York, pp. 131–40.
Lieberman, A. N., Goldstein, M., Gopinathan, G., Leibowitz, M., Neophy-tides, A., Walker, R., Heisser, E. and Nelson, J. (1982). Further studies with pergolide in Parkinson’s disease. Neurology, 32, 1181–4.
Lieberman, A., Gopinathan, G., Hassouri, H., Neophytides, A. and Goldstein, M. (1984). Should dopamine agonists be given early or late? A review of nine years’ experience with bromocriptine. Can. J. Neurol. Sci., 11, 233–7.
Marsden, C. D., Barry, P. E., Parkes, J. D. and Zilkha, K. J. (1973). Treatment of Parkinson’s disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral dopa-decarboxylase. J. Neurol. Neurosurg. Psychiatr., 36, 10–14.
Marsden, C. D., Parkes, J. D. and Quinn, N. (1982). Fluctuations in disability in Parkinson’s disease — clinical aspects. In Marsden, C. D. and Fahn, S. (eds), Movement Disorders. Butterworth Scientific, London, pp. 96–122.
Muenter, M. D. (1984). Should levodopa therapy be started early or late? Can. J. Neurol. Sci., 11 (1), 195–9.
Rascol, A., Montastruc, J. L. and Rascol, O. (1984). Should dopamine agonists be given early or late in the treatment of Parkinson’s disease? Can. J. Neurol. Sci., 11 (1), 229–32.
Reilly, D. K., Hershey, L., Rivera-Calimlin, L. and Shoulson, I. (1983). On-off effects in Parkinson’s disease. A controlled investigation of ascorbic acid therapy. In Fahn, S., Calne, D. B. and Shoulson, I. (eds), Advances in Neurology, vol. 37: Experimental Therapeutics of Movement Disorders. Raven Press, New York, pp. 51–9.
Rinne, U. K. (1983) Dopamine agonists in the treatment of Parkinson’s disease. In Fahn, S., Calne, D. B. and Shoulson, I. (eds), Advances in Neurology, Vol. 37: Experimental Therapeutics of Movement Disorders. Raven Press, New York, pp. 141–50.
Schneider, E., Hubener, K. and Fischer, P. A. (1983). Treatment of Parkinson’s disease with 8-alpha-amino-ergoline, Cu 32–085. Neurology, 33, 468–72.
Tanner, C. M., Goetz, C. G., Glantz, R. H., Glatt, S. L. and Klawans, H. L. (1982). Pergolide mesylate and idiopathic Parkinson’s disease. Neurology, 32, 1181–4.
Teychenne, P. F., Berstrud, D., Racy, A., Elton, R. L. and Vern, B. (1982). Bro-mocriptine: low-dose therapy in Parkinson’s disease. Neurology, 32, 577–83.
Ulm, G. (1983). Experiences with lisuride in the treatment of Parkinson’s disease. In Calne, D. B., Horowski, R., McDonald, R. J. and Wuhke, W. (eds), Lisuride and Other Dopamine Agonists. Raven Press, New York, pp. 463–72.
Yahr, M. B., (1984). Limitations of long-term use of anti-parkinson drugs. Can. J. Neurol. Sci., 11 (1), 191–4.
Editor information
Editors and Affiliations
Copyright information
© 1988 The contributors
About this chapter
Cite this chapter
Lataste, X., Findley, L.J. (1988). Methodology of clinical trials in Parkinson’s disease. Part I: Analysis of previous clinical trials. In: Capildeo, R., Orgogozo, J.M. (eds) Methods in Clinical Trials in Neurology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-08943-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-349-08943-7_11
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-08945-1
Online ISBN: 978-1-349-08943-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)